You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Baxter
Colorcon
AstraZeneca
Mallinckrodt

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,404,276


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,404,276 protect, and when does it expire?

Patent 8,404,276 protects INBRIJA and is included in one NDA.

This patent has twenty patent family members in twelve countries.

Summary for Patent: 8,404,276
Title:Pulmonary delivery for levodopa
Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.
Inventor(s): Jackson; Blair (Quincy, MA), Bennett; David J. (Brighton, MA), Bartus; Raymond T. (San Diego, CA), Emerich; Dwaine F. (Cranston, RI)
Assignee: Civitas Therapeutics, Inc. (Chelsea, MA)
Application Number:12/972,824
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 8,404,276

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Acorda INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 RX Yes Yes   Start Trial   Start Trial INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,404,276

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2003218307   Start Trial
Canada 2478980   Start Trial
Cyprus 1118517   Start Trial
Denmark 1531798   Start Trial
Denmark 2630954   Start Trial
European Patent Office 1531798   Start Trial
European Patent Office 2494962   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Dow
Harvard Business School
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.